سعر دابافلداكتين 5 مجم 28 قرص مغلف 2025

Dapaveldactin 5 mg 28 f.c. tabs.: dapagliflozin 5 mg film-coated tablets, 28-tablet pack (Liptis).

• Adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus (adults and pediatric patients ≥10 years per US label).DailyMed / FDA FARXIGA
• Reduce risk of hospitalization for heart failure in adults with T2DM and established CV disease or multiple CV risk factors (US FARXIGA).DailyMed / FDA FARXIGA

• Common (≥5%): female genital mycotic infections, nasopharyngitis, urinary tract infections.International label, same formulation · DailyMed / FDA FARXIGA

• History of serious hypersensitivity to dapagliflozin or any FARXIGA excipients.International label, same formulation · DailyMed / FDA FARXIGA

• Ketoacidosis risk (including in T2DM); volume depletion; genitourinary infections including Fournier gangrene; hypoglycemia with insulin/secretagogues. Not for glycemic control in T1DM or when eGFR <45 for glycemic indication.International label, same formulation · DailyMed / FDA FARXIGA

• Insulin or insulin secretagogues (e.g. sulfonylureas)ModerateMay increase hypoglycemia risk; consider lower dose of insulin/secretagogue.DailyMed / FDA FARXIGA
• LithiumModerateSGLT2 inhibitors may decrease serum lithium; monitor more frequently on initiation/dose change.DailyMed / FDA FARXIGA

• Not recommended in second and third trimesters based on animal renal developmental toxicity; limited human data. Breastfeeding not recommended (US FARXIGA PLLR).International label, same formulation · DailyMed / FDA FARXIGA

• Dapagliflozin: Inhibits SGLT2 in proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion; also increases sodium delivery to the distal tubule.